Sponsor: NRG
Sponsor Study ID: BR008
Study Title: A Phase III Randomized Trial of Radiotherapy Optimization for Low Risk HER2 Positive Breast Cancer\" (HERO)
CTO #: 103896
NCT Number: NCT05705401
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To compare the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the current standard of care.